CA3043499A1 - Polymorphic form of sepiapterin - Google Patents

Polymorphic form of sepiapterin Download PDF

Info

Publication number
CA3043499A1
CA3043499A1 CA3043499A CA3043499A CA3043499A1 CA 3043499 A1 CA3043499 A1 CA 3043499A1 CA 3043499 A CA3043499 A CA 3043499A CA 3043499 A CA3043499 A CA 3043499A CA 3043499 A1 CA3043499 A1 CA 3043499A1
Authority
CA
Canada
Prior art keywords
sepiapterin
crystalline form
crystalline
free base
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3043499A
Other languages
English (en)
French (fr)
Inventor
Hiroshi Yoshino
Taichi KOMODA
Takayoshi Matsumoto
Kaito KISHIMOTO
Shunichi MURATA
Yuichi Shiro
Daniel E. Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics MP Inc
Original Assignee
Censa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Censa Pharmaceuticals Inc filed Critical Censa Pharmaceuticals Inc
Publication of CA3043499A1 publication Critical patent/CA3043499A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3043499A 2016-11-29 2017-11-28 Polymorphic form of sepiapterin Pending CA3043499A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29
US62/427,686 2016-11-29
PCT/US2017/063515 WO2018102314A1 (en) 2016-11-29 2017-11-28 Polymorphic form of sepiapterin

Publications (1)

Publication Number Publication Date
CA3043499A1 true CA3043499A1 (en) 2018-06-07

Family

ID=62241955

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043499A Pending CA3043499A1 (en) 2016-11-29 2017-11-28 Polymorphic form of sepiapterin

Country Status (8)

Country Link
US (2) US11130760B2 (enExample)
EP (1) EP3548487A4 (enExample)
JP (1) JP7148532B2 (enExample)
CN (1) CN110312721A (enExample)
CA (1) CA3043499A1 (enExample)
MA (1) MA46972A (enExample)
MX (1) MX391156B (enExample)
WO (1) WO2018102314A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
CA3102070A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
EP3801534A4 (en) 2018-05-30 2022-03-16 PTC Therapeutics MP, Inc. COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE
ES2994060T3 (en) 2019-08-05 2025-01-16 Ptc Therapeutics Mp Inc Use of sepiapterin and metabolites thereof to treat radiation exposure
KR20220070477A (ko) 2019-09-25 2022-05-31 피티씨 테라퓨틱스 엠피, 인크. 고페닐알라닌혈증 치료 방법
AU2021209935A1 (en) 2020-01-24 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating Parkinson's disease with sepiapterin
WO2022173823A1 (en) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
JP2024506336A (ja) 2021-02-09 2024-02-13 ピーティーシー セラピューティクス エムピー，インコーポレイテッド 膠芽腫の治療方法
WO2023055923A1 (en) * 2021-09-29 2023-04-06 Ptc Therapeutics, Inc. Pharmaceutical composition of sepiapterin
CN117117299B (zh) * 2023-08-14 2024-12-06 国联汽车动力电池研究院有限责任公司 一种无机硫化物固体电解质及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
ES2177654T3 (es) 1994-08-05 2002-12-16 Suntory Ltd Remedio contra la degeneracion espinocerebelosa.
EP0854934A4 (en) 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
WO2005041975A1 (en) 2003-10-31 2005-05-12 Altana Pharma Ag Use of bh4 for the treatment of respiratory diseases
JP2007536210A (ja) 2003-11-17 2007-12-13 メルック・エプロバ・アクチエンゲゼルシヤフト （６ｒ）−ｌ−エリスロ−テトラヒドロビオプテリンジヒドロクロライドの結晶形
HUE029533T2 (en) 2003-11-17 2017-03-28 Biomarin Pharm Inc Treatment of phenylketonuria with BH4
AU2004290692A1 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
EP2436379A1 (en) 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
EP1819340A2 (en) 2004-12-08 2007-08-22 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
DK3461503T3 (da) 2007-04-11 2022-02-14 Biomarin Pharm Inc Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
NZ588379A (en) 2008-03-10 2012-07-27 Takeda Pharmaceutical Crystal of benzimidazole compound
ES2736730T3 (es) 2008-08-12 2020-01-07 Orpha Swiss Gmbh Forma de administración farmacéutica que contiene tetrahidrobiopterina
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
EP2680848A4 (en) 2011-03-01 2014-11-05 Rubicon Res Private Ltd STABLE TETRAHYDROBIOPTERINE COMPOSITIONS
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
ES2681345T3 (es) * 2012-05-07 2018-09-12 Shiratori Pharmaceutical Co., Ltd. Método para producir sepiapterina y tetrahidrolactoilpterina
AU2017286544B2 (en) 2016-06-13 2022-10-20 Meharry Medical College Modulation of the nitric oxide synthase pathway for oral health
JP2019527242A (ja) 2016-07-29 2019-09-26 ディファーマ エッセ．ア． サプロプテリンジヒドロクロリドを含む医薬組成物キット
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
TWI765936B (zh) 2016-11-29 2022-06-01 美商東京威力科創Ｆｓｉ股份有限公司 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
CA3102070A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
EP3801534A4 (en) 2018-05-30 2022-03-16 PTC Therapeutics MP, Inc. COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
ES2994060T3 (en) 2019-08-05 2025-01-16 Ptc Therapeutics Mp Inc Use of sepiapterin and metabolites thereof to treat radiation exposure
KR20220070477A (ko) 2019-09-25 2022-05-31 피티씨 테라퓨틱스 엠피, 인크. 고페닐알라닌혈증 치료 방법

Also Published As

Publication number Publication date
US20200010469A1 (en) 2020-01-09
US20220081443A1 (en) 2022-03-17
WO2018102314A1 (en) 2018-06-07
MA46972A (fr) 2019-10-09
JP7148532B2 (ja) 2022-10-05
US12325706B2 (en) 2025-06-10
US11130760B2 (en) 2021-09-28
EP3548487A1 (en) 2019-10-09
EP3548487A4 (en) 2020-04-29
JP2020500931A (ja) 2020-01-16
MX391156B (es) 2025-03-21
CN110312721A (zh) 2019-10-08
MX2019006207A (es) 2019-11-18

Similar Documents

Publication Publication Date Title
US12325706B2 (en) Polymorphic form of sepiapterin
US12269829B2 (en) Polymorphs of sepiapterin and salts thereof
JP7778477B2 (ja) セピアプテリンの薬学的に許容される塩
CN106255685A (zh) 用于预防或治疗疟疾的三氨基嘧啶化合物
NZ794827A (en) Polymorphs of sepiapterin and salts thereof
BR122025000511A2 (pt) Forma cristalina de base livre de sepiapterina, composição farmacêutica que a compreende, uso da mesma e método de preparação de uma formulação líquida
BR112019010222B1 (pt) Formas d e f cristalinas de base livre de sepiapterina, suas composições, usos e método de preparação de uma formulação líquida compreendendo as mesmas
BR122025000503A2 (pt) Forma cristalina de base livre de sepiapterina, composição farmacêutica que a compreende, uso da mesma e método de preparação de uma formulação líquida
WO2025228973A1 (en) Cocrystals of n-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928